[NFS-01-3] 高分子Aβオリゴマーはアルツハイマー病の疾患修飾アプローチに向けて重要なターゲットである
Alzheimer's disease (AD) is the most common neurodegenerative disorder and affects over 40 million patients worldwide, but no causative or preventive treatment is currently available. However, recent researches have gradually elucidated new pathogenesis of AD and other dementia disease, and researches linking to disease modification therapies (DMTs) are also progressing. In this symposium, we introduce cutting-edge approaches for DMTs development of AD and other demnetia diseases, and discuss their translational possibilities and issues to be resolved.
Education
1997 M.D. Showa University School of Medicine
2002 Ph.D. Kanazawa University Graduate School of Medical Science
Research and Professional Experience:
2007-2009Postdoctoral Scholar, Department of Neurology, David Geffen School of Medicine, UCLA
2009-2011Instructor, Department of Neurology, Kanazawa University Hospital
2011-2015Associate Professor, Department of Neurology, Neurobiology and Aging,
Kanazawa University Graduate School of Medical Science
2015-presentProfessor, Department of Neurology, Showa University School of Medicine
Awards and Honors:
2010The Award of Showa University School of Medicine Alumni Association
2013 10th Kanazawa University Medical Award
2015Japanese Society of Neurology Award
2016Medical Research Encouragement Prize of The Japan Medical Association
The Award for Distinguished Investigator of Japanese Society for Neurochemistry
2017 Japanese Society of Neurological Therapeutics Award
Kazato Prize (Kazato Research Foundation)
抄録パスワード認証
パスワードは抄録集に記載してあります。